PROBLEM TO BE SOLVED: To provide a novel PDL1 expression induction agent, and a novel immune inhibitor having a different action mechanism from the conventional immune inhibitors.SOLUTION: The present invention provides a PDL1 expression induction agent having entecavir, tenofovir or adefovir as an active ingredient, and an immune inhibitor having entecavir, tenofovir or adefovir as an active ingredient.SELECTED DRAWING: NoneCOPYRIGHT: (C)2020,JPO&INPIT【課題】新たなＰＤＬ１発現誘導剤を提供すること、並びに従来の免疫抑制剤とは異なる作用機序を有する新たな免疫抑制剤を提供すること。【解決手段】エンテカビル、テノホビルまたはアデホビルを有効成分として含む、ＰＤＬ１発現誘導剤、並びにエンテカビル、テノホビルまたはアデホビルを有効成分として含む、免疫抑制剤。【選択図】なし
